Global review confirms mRNA vaccines are safe, effective and full of promise 

Political and policy context

• Many comments veer into US politics: appointments of vaccine‑skeptic health officials, “loyalty over competence,” and contrasts between earlier and current administrations.
• Debate over who deserves credit or blame for fast‑tracking COVID vaccines and for decisions on gain‑of‑function research funding and pandemic preparedness.
• Some argue corporate welfare for pharma has become a partisan issue.

Effectiveness and goals of mRNA COVID vaccines

• Multiple commenters stress vaccines were primarily to reduce severe disease, hospitalization, and death, not to guarantee zero infection.
• Others push back, citing early official statements that implied prevention of infection and transmission, calling later reframing “gaslighting.”
• Several references and anecdotes claim large reductions in hospitalization and mortality among vaccinated populations.

Side effects, myocarditis, and blood clots

• Broad agreement that side effects exist but are rare; myocarditis in young males is discussed heavily.
• Links are shared showing myocarditis/pericarditis risk from COVID infection is much higher than from mRNA vaccination, though critics argue some studies focus on older cohorts or undercount asymptomatic cases.
• Adenovirus‑vector vaccines (e.g., AstraZeneca, J&J) are distinguished from mRNA, with documented rare clotting syndromes leading to their withdrawal or restriction.
• “Calamari”-like clots and embalmer reports are raised; others demand data and label this as unsubstantiated or driven by social media.

Mandates, ethics, and risk tradeoffs

• Strong resentment from some who felt coerced by job mandates, especially younger or previously infected people.
• Others argue all public policy is a trolley‑problem‑like tradeoff between individual risk and collective benefit; vaccine deaths must be weighed against many more preventable COVID deaths.
• Disagreement over whether mandates were justified given non‑sterilizing vaccines, and whether they caused long‑term damage to trust.

Trust, transparency, and institutions

• Repeated theme: distrust of governments, regulators, and “big pharma,” fueled by past scandals, perceived propaganda, and censorship.
• Some say no amount of new reviews will sway committed skeptics; others call for more transparent risk numbers, better communication, and open debate rather than suppression.

mRNA platform potential

• Several are excited about applications beyond infectious disease, especially personalized cancer vaccines and faster flu vaccines, enabled by the pandemic‑driven manufacturing scale‑up.
• A minority points to curated databases of papers on adverse effects as evidence that safety and “full of promise” claims are not universally accepted.